BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-SOD readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-SOD\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06351592-7568@assetmemo.bio
DTSTAMP:20261121T005729Z
DTSTART;VALUE=DATE:20320321
DTEND;VALUE=DATE:20320322
SUMMARY:ALN-SOD: Phase 1/2 readout est. (NCT06351592)
DESCRIPTION:ALN-SOD\, phase 1/2\, Amyotrophic Lateral Sclerosis.\nStudy: Fi
 rst in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic
  Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)\nE
 stimated primary completion: 21 March 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/aln-sod#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06351592
URL:https://assetmemo.bio/drug/aln-sod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
